Publication: Implications of maraviroc and/or rapamycin in a mouse model of fragility.
Loading...
Identifiers
Date
2020-04-30
Authors
Pérez-Martínez, Laura
Romero, Lourdes
Muñoz-Galván, Sandra
Verdugo-Sivianes, Eva M
Rubio-Mediavilla, Susana
Oteo, José A
Carnero, Amancio
Blanco, José-Ramón
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
As age increases, the risk of developing fragility also increases. Improving the knowledge of frailty could contribute to maintaining the functional ability of elderly people. Interleukin (IL)-10 homozygous knockout mice (IL-10tm/tm [IL10KO]) constitute an excellent tool for the study of frailty. Because patients with frailty demonstrate an overexpression of CCR5, rapamycin (RAPA) and/or maraviroc (MVC), two molecules able to decrease CCR5 expression, were evaluated. Muscle myostatin was reduced in all the therapeutic groups but the MVC group (p MVC and RAPA show a protective role in some factors involved in frailty. More studies are needed to prove their clinical applications. Eighty male homozygous IL10KOs were randomly assigned to one of 4 groups (n= 20): i) IL10KO group (IL10KO); ii) IL10KO receiving MVC in drinking water (MVC group), iii) IL10KO receiving RAPA in drinking water (RAPA group), and finally, iv) MVC-RAPA group that received MVC and RAPA in drinking water. Blood and muscle samples were analysed. Survival analysis, frailty index calculation, and functional assessment were also performed.
Description
MeSH Terms
Aging
Animals
Cytokines
Disease Models, Animal
Frailty
Interleukin-10
Male
Maraviroc
Mice
Mice, Knockout
Muscle, Skeletal
Random Allocation
Receptors, Chemokine
Sirolimus
Survival Rate
Animals
Cytokines
Disease Models, Animal
Frailty
Interleukin-10
Male
Maraviroc
Mice
Mice, Knockout
Muscle, Skeletal
Random Allocation
Receptors, Chemokine
Sirolimus
Survival Rate
DeCS Terms
CIE Terms
Keywords
CCR5 antagonist, frailty, myostatin, rapamycin